Ultra-fast HPLC-ICP-MS analysis of oxaliplatin in patient urine

Analytical and Bioanalytical Chemistry

Volumn 397, Issue 1, 2010, Pages 401-406

  Koellensperger, Gunda ^a   Hann, Stephan ^a  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

HPLC; ICP MS; Oxaliplatin

Indexed keywords

CYCLE TIME; HPLC ICP MS; HUMAN URINE; LIMITS OF DETECTION; NOVEL METHODS; OXALIPLATIN; RAPID MEASUREMENT; ULTRA-FAST;

BODY FLUIDS; INDUCTIVELY COUPLED PLASMA; INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY; MASS SPECTROMETERS; PARTICLE SIZE ANALYSIS;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTINEOPLASTIC AGENT; OXALIPLATIN; PLATINUM COMPLEX;

CONFERENCE PAPER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; METHODOLOGY; URINE;

ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MASS SPECTROMETRY; ORGANOPLATINUM COMPOUNDS;

EID: 77951255725     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-010-3504-3     Document Type: Conference Paper

References (16)

1. MA Graham GF Lockwood D Greenslade S Brienza M Bayssas E Gamelin 2000 Clin Cancer Res 6 1205 1218 1:CAS:528:DC%2BD3cXjtVOqsbk%3D
2. E Jerremalm I Wallin H Ehrsson 2009 J Pharm Sci 98 3879 3885 10.1002/jps.21732 1:CAS:528:DC%2BD1MXhtF2qtLfK
3. B Gammelgaard B Packert Jensen 2007 J Anal Atom Spectrom 22 235 249 10.1039/b614911a 1:CAS:528:DC%2BD2sXit12kt7g%3D (Pubitemid 46353905)
4. JJ van Deemter FJ Zuiderweg A Klinkenberg 1956 Chem Eng Sci 5 271 289 10.1016/0009-2509(56)80003-1
5. RE Majors 2006 LC-GC Europe 19 352 362 1:CAS:528:DC%2BD28XmsVGqtr0%3D
6. FR Luo T-Y Yen SD Wyrick SG Chaney 1999 J Chromatogr B 724 345 356 10.1016/S0378-4347(98)00565-9 1:CAS:528:DyaK1MXitFWqsr4%3D (Pubitemid 29148096)
7. Analytical Methods Technical Committee of the Chemistry Manufacturing Controls Coordinating Committee (CMC CC) of the Center for Drug Evaluation and Research at the Food and Drug Administration, Reviewer Guidance "Validation of Chromatographic Methods", 1994, page 22.
8. W Zhang L Seymour EX Chen 2008 J Chrom B 876 277 282 10.1016/j.jchromb. 2008.10.055 1:CAS:528:DC%2BD1cXhsVCntLfK
9. H Ehrsson I Wallin 2003 J Chrom B 795 291 294 10.1016/S1570-0232(03) 00590-7 1:CAS:528:DC%2BD3sXns1KltLs%3D (Pubitemid 37186798)
10. C Eiden L Philibert K Bekhtari S Poujol F Malosse F Pinguet 2009 Am J Health Syst Pharm 66 1929 1933 10.2146/ajhp090039 1:CAS:528:DC%2BD1MXhsV2jtrfM
11. MA Graham GF Lockwood D Greenslade S Brienza M Bayssas E Gamelin 2000 Clin Cancer Res 2000 1205 1218
12. P Allain O Heudi A Cailleux A Le Bouil F Larra M Boisdron-Celle E Gamelin 2000 Drug Metab Dispos 28 1379 1384 1:CAS:528:DC%2BD3cXnsFOlsbg%3D
13. E Jerremalm M Hedeland I Wallin U Bondesson H Ehrsson 2004 Pharm Res 21 891 894 10.1023/B:PHAM.0000026444.67883.83 1:CAS:528:DC%2BD2cXjs1Kjuro%3D (Pubitemid 39011316)
14. J Kragten 1994 Analyst 119 2161 2166 10.1039/an9941902161 1:CAS:528:DyaK2MXhsVSgsLg%3D
15. EURACHEM (2000) Quantifying uncertainty in analytical measurement, 2nd edn. UK, London
16. T Falta G Koellensperger A Standler W Buchberger RM Mader S Hann 2009 J Anal At Spectrom 24 1336 1342 10.1039/b907011g 1:CAS:528:DC%2BD1MXhtFGks7bJ